ClinicalTrials.gg
CompletedNCT07040787Updated Aug 20, 2025

Investigation of Drug-drug Interaction of HRS-5965 With Clopidogrel and Clarithromycin in Healthy Subjects

A Phase 1 interventional study of HRS-5965 Capsules and Clopidogrel in Complement Mediated Glomerular Diseases and Hemolytic Anemia, sponsored by Chengdu Suncadia Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-20.

Sponsored by Chengdu Suncadia Medicine Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Non-randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The study is being conducted to compare the drug-drug interaction of HRS-5965 with clopidogrel and clarithromycin in healthy subjects.

02

Conditions studied

  • Complement Mediated Glomerular Diseases
  • Hemolytic Anemia

Browse trials for

03

In context

Anemia, Hemolytic

56 studies on the registry are indexed under Anemia, Hemolytic; 16 are open to participants now.

This study's enrollment of 36 is below the median of 48 across 39 interventional studies indexed under Anemia, Hemolytic.

Browse Anemia, Hemolytic studies →

Lead sponsor

Chengdu Suncadia Medicine Co., Ltd. is the lead sponsor of 24 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Ability to understand the study procedures and methods, participate voluntarily and be able to complete the study according to the protocol requirements, and sign the form (ICF) in writing.
  2. Aged 18-45 years old on the date of signing the ICF (including the threshold), both male and female.
  3. At the time of screening, male subjects weighing no less than 50 kg and female subjects weighing no less than 45 kg; (BMI): 19\~26 kg/m2 (including the threshold).
  4. During the screening period, antibody (HIV-Ab), treponema pallidum antibody, surface antigen (HBsAg) and virus antibody (HCV-Ab) were all negative.
  5. Female subjects with reproductive capacity or male subjects whose partners are female subjects with reproductive capacity need to have no plans for fertility or sperm/egg donation within 3 months +1 week for male subjects and 6 months +1 week for female subjects from the date of signing the informed consent form until the last medication use, and voluntarily take efficient measures (including partners).

Exclusion criteria

Exclusion Criteria:

  1. Allergic to two or more allergens, or in the judgment of the investigator, may be allergic to the study drug or its components.
  2. Disease or medical condition that, in the judgment of the investigator, may interfere with the absorption, distribution, metabolism, and excretion of the drug or that may reduce compliance.
  3. Patients with a previous history of coronary artery disease, severe cardiac insufficiency, conduction disorders or bradycardia.
  4. Patients with a history of electrolyte disorders (such as hypomagnesemia).
  5. Patients with a history of congenital or acquired prolongation or ventricular arrhythmia.
  6. Those with a history of meningococcal infection and streptococcus pneumoniae infection.
  7. Those with a history of neuromuscular diseases (such as myotonic dystrophy, poliomyelitis, myasthenia gravis, botulism poisoning) and poliomyelitis.
  8. Subjects who have had or are currently suffering from active pathological bleeding.
  9. Subjects with a previous history of recurrent oral ulcers.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Drug-drug interaction between HRS-5965 and clopidogrel

    Drug: HRS-5965 Capsules · Drug: Clopidogrel

  • Experimental
    Drug-drug interaction between HRS-5965 and clarithromycin

    Drug: HRS-5965 Capsules · Drug: Clarithromycin

Interventions

06

What researchers measure

Primary outcomes

  1. The maximum plasma concentration (Cmax)

    Time frame: Day 1 to day 12.

  2. Area under the concentration curve from time 0 to the last quantifiable concentration (AUClast)

    Time frame: Day 1 to day 12.

Secondary outcomes

  1. Time to maximum plasma concentration

    Time frame: Day 1 to day 12.

  2. Terminal half-life (t1/2)

    Time frame: Day 1 to day 12.

  3. Incidence and severity of adverse events (AEs)

    Time frame: Day 1 up to day 19.

07

Study locations

1 site
  • The First Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi 330019, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2025 to primary completion in Aug 2025, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2025
First posted
Jun 27, 2025
StartActual
Jul 8, 2025
Primary completionActual
Aug 17, 2025
CompletionActual
Aug 17, 2025
Last update
Aug 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07040787
Responsible party
Sponsor
First posted
Jun 27, 2025
Start date
Jul 8, 2025
Primary completion
Aug 17, 2025
Completion
Aug 17, 2025
Last update
Aug 20, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: HRS-5965 · Clopidogrel

Start the discussion